- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03651648
Apnea Treatment in Premature Infants Using an Automatic Vibro-tactile Stimulator Triggered by the Detection of Apnea-bradycardia. (SENSITACT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main hypothesis behind the SENSITACT system is that kinesthetic stimulation can terminate apneas-bradycardias with minimal patient arousal. The aim is to stimulate mechanoreceptors through the skin by kinesthetic stimulation on the lower abdominal zone. This is a region of the body that is covered with Pacinian corpuscles, a very sensitive kind of mechanoreceptors, which respond to rapid vibrations on the skin (200-300 Hz). Vibro-tactile stimulation of these mechano-receptors will trigger a reaction typical of the startle reflex. This reflex causes 1) an immediate myotonic reaction and 2) a widespread autonomic response. The former should have a direct effect on obstructive respiratory disorders with an increase in chin muscle tones within 80 to 100 ms. The latter should act on central respiratory disorders, with activation of the sympathetic nervous system. Since both responses are mediated via sub-cortical nervous center, it is expected that patient arousal will be limited. Preliminary clinical studies on adult patients conducted by LTSI, Sorin CRM and CHU de Grenoble (Skin&SAS, HYPNOS, EKINOx), that have used the same PASITHEA stimulation device have confirmed activation of the sympathetic nervous system and a significant reduction in the duration of apnea or hypopnea events, while no differences were observed on patients' sleep architecture.
The SENSITACT system is able to detect apneas-bradycardias in real-time, so that kinesthetic stimulation can be triggered to stop respiratory disorders very early during the event. Detection is performed within the SENSITACT controller station that receives data from all sensors connected to the Patient Monitor in real-time. As soon as the early signs of an apnea-bradycardia are detected, the SENSITACT controller sends a trigger signal to the PASITHEA stimulator that immediately activates kinesthetic stimulation.
Kinesthetic stimulation is stopped when a normal condition (normal cardiac rhythm) is detected or when a maximum number of stimulation pulses have been reached.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Patrick PLADYS, Pr
- Phone Number: 06 34 19 11 30
- Email: patrick.pladys@chu-rennes.fr
Study Locations
-
-
-
Rennes, France, 35200
- Recruiting
- CHU de Rennes
-
Contact:
- Patrick PLADYS, Pr
- Email: patrick.pladys@chu-rennes.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- written informed consent,
Premature infants,
- born to a term less than 34 weeks of amenorrhea (AS),
- Age less than 36 weeks post-menstrual age,
- With a postnatal age greater than 4 days,
- caffeine treated, for at least 36 hours,
- Presenting episodes of bradycardia apnea significant (>10 sec with bradycardia <100 bpm or SaO2<80%) with an interval of less than 6 hours between two episodes observed in the 24 hours preceding inclusion.
Exclusion Criteria:
- Major congenital neurological abnormalities,
- Congenital abnormalities of the respiratory tracts,
- HIV grade 3 or 4,
- Periventricular leukomalacia,
- Invasive ventilation and non-invasive ventilation in NAVA mode,
- Cyanogenic malformative heart disease,
- Sepsis diagnosed in the 4 days prior to registration (CRP> 10mg / L),
- maternal addiction during pregnancy,
- Father and / or mother legally protected (under judicial protection, guardianship or supervision).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SENSITACT System ON
As soon as the early signs of an apnea-bradycardia are detected, the SENSITACT controller sends a trigger signal to the PASITHEA stimulator that immediately activates kinesthetic stimulation
|
the activated stimulation (ON period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
Other Names:
the desactivated stimulation (OFF period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
Other Names:
|
Sham Comparator: SENSITACT System OFF
The SENSITACT controller doesnt send any trigger signal to the PASITHEA stimulator even if an early sign of an apnea-bradycardia is detected.
|
the activated stimulation (ON period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
Other Names:
the desactivated stimulation (OFF period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative duration of apnea-bradycardia
Time Frame: 12 hours (H12)
|
Cumulative duration of apnea-bradycardia over a period of 6 hours with stimulation activated or not.
|
12 hours (H12)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distribution of bradycardia durations
Time Frame: 12 hours (H12)
|
A bradycardia is defined by an acute event lasting at least 5 seconds with a decrease in heart rate of more than 33% of the basal heart rate (median of heart measured on 5-min stationary periods during quiet sleep). The distribution of the durations will be quantified in terms of median, IQR and distribution curve |
12 hours (H12)
|
Depth of bradycardia
Time Frame: 12 hours (H12)
|
A bradycardia is defined by an acute event lasting at least 5 seconds with a decrease in heart rate of more than 33% of the basal heart rate (median of heart measured on 5-min stationary periods during quiet sleep). The depth of bradycardia will be measured by the area under the curve with the upper limit of the curve defined by the value of "basal heart rate-33%" and expressed in beats/min*sec The distribution of the depth of bradycardias will be quantified in terms of median, IQR and distribution curve |
12 hours (H12)
|
Depth of desaturations
Time Frame: 12 hours (H12)
|
The depth of desaturation will be measured by the area under the curve with the upper limit of the curve set at a Saturation of 80% The distribution of the depth of desaturations will be quantified in terms of median, IQR and distribution curve
|
12 hours (H12)
|
Caregiver interventions
Time Frame: 12 hours (H12)
|
The number of caregiver interventions associated with a cardio-respiatory event will be quantified and expressed in number/hour
|
12 hours (H12)
|
Cardiorespiratory parameters in response to stimulation
Time Frame: 6 hours (H6)
|
The delay between the initiation of stimulation and the first breath will be measured and expressed in median IQR The delay between the initiation of stimulation and the normalization of heart rate above the limit of "basal heart rate-33%" will be measured and expressed in median IQR The delay between the initiation of stimulation and the observation of a Saturation above 80% will be measured and expressed in median IQR
|
6 hours (H6)
|
Premature's sleep-wake cycles
Time Frame: 12 hours (H12)
|
Duration of the stages identified
|
12 hours (H12)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Patrick PLADYS, Pr, Rennes University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Signs and Symptoms, Respiratory
- Arrhythmias, Cardiac
- Pregnancy Complications
- Obstetric Labor Complications
- Obstetric Labor, Premature
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Apnea
- Premature Birth
- Bradycardia
Other Study ID Numbers
- 35RC16_9894_SENSITACT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Apnea of Prematurity
-
University of ManitobaCanadian Institutes of Health Research (CIHR); The Children's Hospital Foundation...Completed
-
Children's Hospital of Fudan UniversityCompletedApnea of Prematurity
-
NobelpharmaCompleted
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingApnea of PrematurityUnited States
-
Daping Hospital and the Research Institute of Surgery...Unknown
-
Mednax Center for Research, Education, Quality...CompletedApnea of PrematurityUnited States
-
Ain Shams UniversityUnknown
-
University of MiamiThe Gerber FoundationCompletedApnea of Prematurity | Periodic Breathing | Desaturation of Blood | Central Apnea | Obstructive Apnea of NewbornUnited States
-
Wyss Institute at Harvard UniversityBeth Israel Deaconess Medical Center; University of Massachusetts, WorcesterCompletedApnea of PrematurityUnited States
-
McMaster UniversityNational Health and Medical Research Council, Australia; Canadian Institutes...CompletedApnea of PrematurityCanada, United States, Israel, Australia, Netherlands, United Kingdom, Switzerland, Germany, Sweden
Clinical Trials on SENSITACT System
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
KineticureCompletedOsteoarthritis | Knee PainUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Molnlycke Health Care ABCompletedEvaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.Diabetes | Foot UlcersUnited Kingdom
-
Zahedan University of Medical SciencesUnknownPain, Postoperative Pain Pathologic Processes Postoperative Complications Signs and Symptoms
-
University of British ColumbiaNot yet recruitingPersistent Developmental Stutter | Childhood-Onset Fluency Disorder (Stuttering)
-
National Institute of Neurological Disorders and...Recruiting